Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2025-04-29 Annual Report
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物2024年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2024 年年度报告摘要" which translates to "2024 Annual Report Summary". It contains detailed financial data for the year 2024, including revenue, net profit, assets, and shareholder information. It also includes management discussion and analysis, business overview, industry analysis, and risk factors. The document is over 12,000 characters long, indicating it is a substantive report rather than a brief announcement. The presence of comprehensive financial data and management commentary aligns with the characteristics of an Annual Report (10-K equivalent). There is no indication that this is merely an announcement or a certification, nor is it a quarterly or interim report. Therefore, the document should be classified as an Annual Report (10-K). FY 2024
2025-04-29 Chinese
安旭生物2024年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2024 by Hangzhou Anxu Biotechnology Co., Ltd. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2024, including financial and non-financial internal control defects, their identification standards, and remediation status. The content is detailed and specific to internal control evaluation rather than a full annual report or audit report. It is not a brief announcement or a certification letter but a substantive report on internal control evaluation. This type of document aligns with an Audit Report / Information (AR) category, which includes standalone audit reports and internal control evaluation results, excluding full annual reports. The document length (4232 characters) is sufficient for a detailed report but not overly long, consistent with an internal control evaluation report rather than a full annual report (10-K) or interim report (IR). Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-04-29 Chinese
安旭生物董事会审计委员会2024年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Board Audit Committee of Hangzhou Anxu Biotechnology Co., Ltd. for the year 2024. It discusses the committee's composition, meetings held, supervision of external auditors, internal audit guidance, review of financial reports for various periods (2023 annual, 2024 Q1, half-year, and Q3 reports), internal control evaluation, and coordination between management and auditors. The content is focused on audit committee activities and oversight rather than the full annual report or standalone audit report. It is not a short announcement or certification but a substantive report on audit committee duties and findings. This fits the category of Audit Report / Information (AR), which includes audit reports, applied accounting principles, and internal or regulatory audit-related information excluding full annual reports. The document is not an Annual Report (10-K) because it does not contain full financial statements or comprehensive company activity details, but rather focuses on audit committee oversight and audit-related matters. FY 2024
2025-04-29 Chinese
民生证券股份有限公司民生证券关于杭州安旭生物科技股份有限公司开展远期结售汇业务的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed opinion and verification report by the sponsor (Minsheng Securities) regarding Hangzhou Anxu Biotechnology Co., Ltd.'s plan to conduct forward foreign exchange settlement and foreign exchange derivative product business. It includes legal references, business purpose, risk analysis, risk control measures, accounting policies, and approval procedures. The document is not a financial report, earnings release, or regulatory filing per se, but rather a formal verification and opinion statement related to a specific business activity and its compliance with laws and regulations. It is not announcing voting results, management changes, or capital changes. It is a regulatory compliance and verification document related to a specific business operation. Given the nature and content, it best fits under Regulatory Filings (RNS) as a general regulatory announcement and compliance document that does not fit other specific categories.
2025-04-29 Chinese
安旭生物关于召开2024年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a notice about the convening of the 2024 Annual General Meeting (AGM) of Hangzhou Anxu Biotechnology Co., Ltd., including details such as the date, voting methods, agenda items, and instructions for shareholders. It does not contain the actual annual report or financial statements but rather the announcement and procedural information for the upcoming AGM. The document length is 3589 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2025-04-29 Chinese
中审众环会计师事务所（特殊普通合伙）关于安旭生物2024年度审计报告
Regulatory Filings
2025-04-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.